RESP Stock Overview
A research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Respiratorius AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.24 |
| 52 Week High | SEK 0.49 |
| 52 Week Low | SEK 0.20 |
| Beta | 1.66 |
| 11 Month Change | 0% |
| 3 Month Change | -2.05% |
| 1 Year Change | -37.76% |
| 33 Year Change | -85.52% |
| 5 Year Change | -88.05% |
| Change since IPO | -8.08% |
Recent News & Updates
Shareholder Returns
| RESP | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.9% |
| 1Y | -37.8% | 30.1% | 24.3% |
Return vs Industry: RESP underperformed the Swedish Biotechs industry which returned -3.2% over the past year.
Return vs Market: RESP underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility
| RESP volatility | |
|---|---|
| RESP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: RESP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RESP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 0 | Johan Drott | www.respiratorius.com |
Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Respiratorius AB (publ) Fundamentals Summary
| RESP fundamental statistics | |
|---|---|
| Market cap | SEK 69.86m |
| Earnings (TTM) | -SEK 7.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.9x
P/E RatioIs RESP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RESP income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 7.83m |
| Earnings | -SEK 7.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 21, 2024
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RESP perform over the long term?
See historical performance and comparison